Skip to main content

Table 2 The detailed differences between survival group and mortality group in heterotaxy syndrome

From: Interstage mortality for functional single ventricle with heterotaxy syndrome: a retrospective study of the clinical experience of a single tertiary center

  Survival group (%) Mortality group (%)
N 23 16
Observation period (mo) 131.1 ± 88.5 32.9 ± 68.9
Male 16 (69.6) 9 (56.3)
Isomerism  
Right 18 (78.3) 15 (93.8)
Left 4 (17.4) 0 (0)
Ambiguous 1 (4.3) 1 (6.3)
Age of 1st palliation (mo) 4.1 ± 3.1 1.5 ± 2.3
1st palliation  
BT shunt 12 (52.2) 13 (81.2)
PAB 1 (4.3) 1 (6.3)
BCPS 10 (43.4) 2 (12.5)
Birth weight (kg)  
< 3p 2 (8.7) 5 (31.3)
3-25p 10 (43.4 6 (37.5)
25-50p 5 (21.7) 3 (18.8)
>50p 6 (26.1) 2 (12.5)
Body weight at discharge (kg)  
< 3p 4 (17.4) 12 (75.0)
3-25p 10 (43.4) 3 (18.8)
25-50p 3 (13.0) 0 (0)
>50p 6 (26.1) 1 (6.3)
AVVR > mild 9 (39.1) 11 (68.8)
Pulmonary atresia 9 (39.1) 7 (43.8)
Pulmonary vein stenosis at diagnosis 4 (17.4) 6 (37.5)
Duration of hospitalization (days) 29.8 ± 17.3 59.1 ± 88.0
Duration of ICU care (days) 9.0 ± 5.9 32.5 ± 48.6
Duration of mechanical ventilation (days) 3.0 ± 2.3 26.4 ± 47.0
Duration of IV inotropics (days) 6.4 ± 6.4 17.8 ± 25.5
Duration of TPN (days) 12.1 ± 11.5 24.0 ± 30.7
Antiarrhythmic at discharge 3 (13.0%) 2 (12.5%)
O2 saturation at discharge (%) 88.1 ± 6.4 78.9 ± 3.3
  1. BT Blalock-Taussig, PAB pulmonary artery banding, BCPS bidirectional cavo-pulmonary shunt, AVVR atrioventricular valve regurgitation, ICU intensive care unit, IV intravenous, TPN total parenteral nutrition.